Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WP103 is a small molecule acetylcholinesterase inhibitor (AChEI) being developed by Wanbangde for the treatment of Neonatal Hypoxic-Ischemic Encephalopathy (HIE). It is a novel injection formulation of huperzine A, a sesquiterpene alkaloid that naturally occurs in the firmoss *Huperzia serrata*. By inhibiting the enzyme acetylcholinesterase, WP103 increases the concentration of acetylcholine in the central nervous system, which is intended to provide neuroprotective effects and mitigate brain injury caused by oxygen deprivation in newborns. The drug has been granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by the US FDA. Its Investigational New Drug (IND) application has been accepted by the FDA, moving the candidate into clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WP103.